EPIRUBICIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Epirubicin Hydrochloride patents expire, and what generic alternatives are available?
Epirubicin Hydrochloride is a drug marketed by Actavis Totowa, Cipla Ltd, Ebewe Pharma, Epic Pharma Llc, Fresenius Kabi Usa, Hikma, Hisun Pharm Hangzhou, Hospira, Impax Labs Inc, Mylan Institutional, Mylan Labs Ltd, and Zennova. and is included in fourteen NDAs.
The generic ingredient in EPIRUBICIN HYDROCHLORIDE is epirubicin hydrochloride. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the epirubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Epirubicin Hydrochloride
A generic version of EPIRUBICIN HYDROCHLORIDE was approved as epirubicin hydrochloride by HIKMA on June 27th, 2007.
Summary for EPIRUBICIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Clinical Trials: | 470 |
Patent Applications: | 5,706 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EPIRUBICIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for EPIRUBICIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Karolinska University Hospital | Phase 2 |
Peng Liu | Phase 2 |
Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
Pharmacology for EPIRUBICIN HYDROCHLORIDE
Drug Class | Anthracycline Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |